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sibling and alternative donors, a FluBu4 backbone  ATG or
low dose radiation was an exceptionally well-tolerated
conditioning regimen that resulted in prompt and reliable
engraftment. Relapse rates and overall survival were similar
to those seen with other myeloablative regimens.301
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With the absence of speciﬁc clinical practice guidelines for
the management of febrile pediatric HSCT patients, many
institutions apply oncology febrile neutropenia guidelines to
pediatric HSCT patients. Recent guidelines regarding the
management of febrile neutropenia in pediatric oncology
patients have questioned the role of sinus CT in their eval-
uation. We sought to determine the predictive factors for
positive ﬁndings on sinus CT and their impact on manage-
ment of febrile pediatric allo-HSCT patients in the ﬁrst year
after transplant. We conducted a retrospective chart review
from 7/1/2007 through 6/30/13. There were 41 febrile epi-
sodes from 37 patients that included sinus CT in the evalu-
ation.19 of the 41 episodes (46%) had positive ﬁndings on the
sinus CT. There was no statistically signiﬁcant difference
between the positive sinus CT and the negative sinus CT
groups with regards to diagnosis, disease status, preparative
regimen, HLA matching/graft source, GVHD, GVHD treat-
ment, presence of NG or ETT, positive blood or urine culture,
or positive ﬁndings on the pre-HSCT sinus CT. The median
time from onset of fever to the sinus CT in the positive sinus
CT group and the negative sinus CT group was not signiﬁ-
cantly different using the log-rank test (256 hrs and 170 hrs,
p¼0.14). Median ANC and APC at onset of fever were signif-
icantly higher in the positive sinus CT group compared to the
negative sinus CT group using the Wilcoxon rank sum test
(2.470109/L and 3.050 109/L versus 0.775109/L and 1.060 109/
L , p¼0.03 and 0.04). 16% of episodes with a positive sinus CT
had no other source of infection identiﬁed, but no episodes
had changes to the pharmacotherapy regimen solely based
on a positive sinus CT. One patient did undergo bilateral
endoscopic maxillary antrostomies and anterior ethmoi-
dostomies, and cultures were positive for Candida glabrata.Sinus CT has a minimal impact on the management of febrile
pediatric allo-HSCT recipients and should be examined in
larger multi-center groups to help develop practice guide-
lines.302
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Alemtuzumab (humanized CD52-monoclonal antibody), a
potent T cell inhibitor, is often included in reduced-intensity
conditioning (RIC) regimens. Modeled on the successes of
such regimens, newer alemtuzumab-containing RIC regi-
mens are being increasingly used for patients with hemo-
globinopathies. We retrospectively reviewed the possible
impact of “late” alemtuzumab (i.e., administered on days -10
through -8) with respect to engraftment and acute/chronic
GvHD in nine pediatric patients (median age 10 y, range 5.1-
18.6yrs)with sickle cell disease who underwent stem cell
transplantation from HLA-matched sibling donors. All pa-
tients received alemtuzumab 10 mg IV daily on days-10
through-8, ﬂudarabine 35 mg/m2/day IV on days-7 to-4, and
melphalan 70 mg/m2 IV on day -3 and day -2. Alemtuzumab
was given relatively close to the day of transplant with intent
to diminish the incidence of graft versus host disease. Eight
out of 9 patients received marrow and 1 patient received
marrow and cord blood. Median nucleated cell dose was 2.3
x 108/kg (Range: 1.46-4.3), with median CD34 cell dose of 1.6
x 106/kg (range: 0.9-5.5). Median time to neutrophil and
platelet engraftment was 15.5 and 36 days, respectively, in
our study. All of the patients received the GvHD prophylactic
regimen comprising of Cyclosporine and Mycophenolate,
both beginning on day -1 of transplant. All patients have
been followed a minimum of 3.5yrs post-transplant.
One patient developed mild acute GvHD of the skin and
another developed limited chronic skin GvHD (taken off
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experienced graft failure within three months and a third
one within 14 months post transplant (two of whom
underwent successful second transplants 12 mos and
18 mos later while the third elected to not undergo
retransplantation and is now transfusion dependent). 6
patients became durably engrafted and remain disease-free.
Since 3 of the 9 patients rejected their grafts, the
conditioning regimen was modiﬁed to include the same
three agents but with alemtuzumab given between days -21
and -19. Results in ﬁve subsequent pts have yielded no
instances of graft rejection. Due to its relatively long half-life
(15-21 days), alemtuzumab, when given close to the day of
stemcell infusion,mayreduce the likelihoodof acuteGvHDbut
may also lead to in-vivo T-cell depletion of the donor graft,
thereby increasing the probability of graft loss. In this small
study, this latter effect outweighed the possible beneﬁt of
reducing the likelihoodof acuteGvHD.Thismaybeparticularly
true in this patient populationwhich comes to transplantation
with an intact, and often sensitized, immune system.303
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Background: Rare diseases requiring hematopoietic stem
cell transplantation present a challenge for pediatric BMT
centers. The patients present at a low frequency, and there
are often no established conditioning regimens for these
disorders. We report the conditioning regimen, donor
source, and outcomes for the following rare disorders
transplanted at our program from January 2011 through
January 2014. During the past three years we have had pa-
tients present with the following: Fanconi anemia (FA),
Hemophagocytic Lymphohistiocytosis (HLH), Congenital
Amegakaryocytic Thrombocytopenia (CAMT), Chediak-
Higashi Syndrome (CHS), Langerhans Cell Histiocytosis
(LCH), Beta-thalassemia, Juvenile Myelomonocytic Leukemia
(JMML), Immunodeﬁciency Syndrome with Myelodysplastic
Syndrome (IDS/MDS), and Cartilage Hair Hypoplasia (CHH).
Methods: We are the sole pediatric HSCT center in our state.
We treat patients with rare disorders that require HSCT at
our center, and are reporting the management strategy and
outcomes for this wide variety of rare disorders.Table 1
Patient characteristics and outcomes for patients with rare disorders.
Patient Disease Donor / HLA Match Conditioning
1 HLH UCB- 5/6 Bu/VP/CY/ATG
2 HLH MSD BM- 10/10 Alem/Flu/Mel
3 FA BM- 10/10 TBI/Flu/CY/ATG
4 B-thal MRD BM- 8/10 Bu/CY/ATG
5 IDS/MDS BM- 9/10 Bu/CY/ATG
6 LCH MSD BM- 10/10 Alem/Flu/Mel
7 CHH MSD UCB- 6/6 Bu/CY/ATG
8 JMML MSD BM- 10/10 Bu/CY/Mel
9 CAMT BM- 10/10 CY/ATG/TBI
10 HLH BM- 9/10 Alem/Flu/Mel
11 CHS BM- 10/10 Bu/CYResults: The patients were referred to or diagnosed at our
institution from January 2011 to January 2014. All patients
were transplanted with the best available donor using bone
marrow (BM) or umbilical cord blood (UCB). Conditioning
regimens and treatment plans were determined by the BMT
attending team based on reviews of the literature and varied
with type of disease. The BMT coordinators and nurse prac-
titioners were educated about the disorders and then
educated the inpatient and outpatient teams. The PharmD
created order sets for patients based on the treatment plans.
Patient characteristics and outcomes are presented in Table 1.
The day 100 survival was 100%. Nine of 11 patients are alive
and well (A/W) with no evidence of disease.
Conclusions: Our program has treated a variety of rare disor-
ders with a > 80% Event-Free-Survival. Our data suggests that
excellent outcomes can be obtained at small-moderate sized
BMT programs when the team approach is used to create the
best-practices plan of care for each individual patient.304
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Background: TMA with high-risk features at diagnosis,
including terminal complement activation measured by
elevated sC5b-9 and proteinuria, is associated with very
high mortality as <20% of such untreated patients survive
at 1 year after HSCT (Jodele et al, Blood 2014). In a thera-
peutic pilot study, we observed TMA resolution in 4 of
6 patients with high-risk TMA who achieved complement
blockade using eculizumab, with dosing guided pharma-
codynamically by measurement of total hemolytic
complement activity (CH50) (Jodele et al, BBMT 2014). We
now present an expanded patient cohort treated with
eculizumab.ANC > 500 (Day) Platelet > 20K (Day) Outcome
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